A new trading day began on Monday, with Processa Pharmaceuticals Inc (NASDAQ: PCSA) stock price up 9.22% from the previous day of trading, before settling in for the closing price of $0.21. PCSA’s price has ranged from $0.15 to $2.12 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 22.65% over the last five years. Meanwhile, its annual earnings per share averaged 81.52%. With a float of $34.95 million, this company’s outstanding shares have now reached $40.28 million.
The firm has a total of 10 workers. Let’s measure their productivity. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Processa Pharmaceuticals Inc (PCSA) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Processa Pharmaceuticals Inc is 13.24%, while institutional ownership is 0.43%. The most recent insider transaction that took place on Jan 27 ’25, was worth 9,889. In this transaction Director of this company bought 12,400 shares at a rate of $0.80, taking the stock ownership to the 12,400 shares. Before that another transaction happened on Jan 27 ’25, when Company’s Chief Executive Officer bought 87,200 for $0.80, making the entire transaction worth $69,542. This insider now owns 87,200 shares in total.
Processa Pharmaceuticals Inc (PCSA) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.12 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 81.52% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 42.13% during the next five years compared to 22.65% growth over the previous five years of trading.
Processa Pharmaceuticals Inc (NASDAQ: PCSA) Trading Performance Indicators
Here are Processa Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 2.93.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.08, a number that is poised to hit -0.22 in the next quarter and is forecasted to reach -0.54 in one year’s time.
Technical Analysis of Processa Pharmaceuticals Inc (PCSA)
Analysing the last 5-days average volume posted by the [Processa Pharmaceuticals Inc, PCSA], we can find that recorded value of 4.11 million was lower than the volume posted last year of 8.95 million. As of the previous 9 days, the stock’s Stochastic %D was 23.14%.
During the past 100 days, Processa Pharmaceuticals Inc’s (PCSA) raw stochastic average was set at 12.75%, which indicates a significant decrease from 44.99% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0212 in the past 14 days, which was lower than the 0.0501 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.2518, while its 200-day Moving Average is $0.5871.
